Haemonetics Acquires Vivasure for €100 Million to Enhance Closure Technology
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 14h ago
0mins
Source: PRnewswire
- Acquisition Deal: Haemonetics has acquired Vivasure Medical for €100 million, aiming to enhance its technological capabilities in the large-bore closure market, thereby increasing its impact in the rapidly growing structural heart and endovascular procedure sectors.
- Technological Innovation: Vivasure's PerQseal®Elite system utilizes a bioabsorbable patch to seal large-bore arteriotomies without sutures, which is expected to significantly improve clinical safety and efficiency in procedures.
- Clinical Performance: The ELITE arterial study demonstrated a 0% major complication rate for PerQseal Elite, achieving rapid hemostasis at the 30-day follow-up, further solidifying Haemonetics' leadership in advanced closure technologies.
- Financial Arrangement: The acquisition includes an upfront cash payment of €100 million, plus up to €85 million in contingent consideration based on sales growth, reflecting Haemonetics' confidence in future market potential.
Analyst Views on HAE
Wall Street analysts forecast HAE stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for HAE is 78.86 USD with a low forecast of 64.00 USD and a high forecast of 90.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 84.040
Low
64.00
Averages
78.86
High
90.00
Current: 84.040
Low
64.00
Averages
78.86
High
90.00
About HAE
Haemonetics Corporation is a global healthcare company. The Company is engaged in providing a suite of medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. The Company’s technology addresses various medical markets, including blood and plasma component collection, the surgical suite, and hospital transfusion services. The Company’s Plasma segment includes plasma collection devices and disposables, donor management software and supporting software solutions sold to plasma customers. Its Blood Center segment manufactures and provides customers with its full line of apheresis solutions for automated blood collection. The Company’s Hospital segment consists of Interventional Technologies, which includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection products, and Blood Management Technologies, which includes Hemostasis Management, Cell Salvage and Transfusion Management products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
